Cargando…

Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts

Background: The analysis of angiogenesis factors in the blood of tumor patients has given diverse results on their prognostic or predictive value. Since mediators of angiogenesis are stored in platelets, their measurement in plasma is sensitive to inadvertent platelet activation during blood process...

Descripción completa

Detalles Bibliográficos
Autores principales: Starlinger, Patrick, Alidzanovic, Lejla, Schauer, Dominic, Brugger, Philipp, Sommerfeldt, Silvia, Kuehrer, Irene, Schoppmann, Sebastian F., Gnant, Michael, Brostjan, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826483/
https://www.ncbi.nlm.nih.gov/pubmed/21896999
http://dx.doi.org/10.3233/DMA-2011-0798
_version_ 1782290913677017088
author Starlinger, Patrick
Alidzanovic, Lejla
Schauer, Dominic
Brugger, Philipp
Sommerfeldt, Silvia
Kuehrer, Irene
Schoppmann, Sebastian F.
Gnant, Michael
Brostjan, Christine
author_facet Starlinger, Patrick
Alidzanovic, Lejla
Schauer, Dominic
Brugger, Philipp
Sommerfeldt, Silvia
Kuehrer, Irene
Schoppmann, Sebastian F.
Gnant, Michael
Brostjan, Christine
author_sort Starlinger, Patrick
collection PubMed
description Background: The analysis of angiogenesis factors in the blood of tumor patients has given diverse results on their prognostic or predictive value. Since mediators of angiogenesis are stored in platelets, their measurement in plasma is sensitive to inadvertent platelet activation during blood processing. Methods: Variants of blood withdrawal and plasma preparation were evaluated by ELISA for the detection of TSP-1, PF-4, VEGF and PD-ECGF. A total of 22 pancreatic cancer patients and 29 healthy volunteers were evaluated. Results: Plasma preparation with the anticoagulant mix of citrate, theophylline, adenosine, dipyridamole (CTAD) and immediate blood processing at 4°C was required for reproducible measurements of TSP-1, PF-4 and VEGF. Blood collection by venflon or inadvertent hemolysis during blood withdrawal caused significantly elevated TSP-1 and PF4 values. When optimized plasma preparation was applied, a significant increase of TSP-1 and VEGF in cancer patients was detected (P = 0.006; P < 0.001). Conclusion: The reliable plasma analysis of circulating platelet-stored angiogenesis factors requires preparation with CTAD at 4°C and blood collection by butterfly needle. Suboptimal procedures of plasma preparation are commonly applied in clinical monitoring of angiogenesis parameters which may account for the differences in reported plasma values and may have masked their predictive or prognostic marker potential.
format Online
Article
Text
id pubmed-3826483
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-38264832013-12-01 Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts Starlinger, Patrick Alidzanovic, Lejla Schauer, Dominic Brugger, Philipp Sommerfeldt, Silvia Kuehrer, Irene Schoppmann, Sebastian F. Gnant, Michael Brostjan, Christine Dis Markers Other Background: The analysis of angiogenesis factors in the blood of tumor patients has given diverse results on their prognostic or predictive value. Since mediators of angiogenesis are stored in platelets, their measurement in plasma is sensitive to inadvertent platelet activation during blood processing. Methods: Variants of blood withdrawal and plasma preparation were evaluated by ELISA for the detection of TSP-1, PF-4, VEGF and PD-ECGF. A total of 22 pancreatic cancer patients and 29 healthy volunteers were evaluated. Results: Plasma preparation with the anticoagulant mix of citrate, theophylline, adenosine, dipyridamole (CTAD) and immediate blood processing at 4°C was required for reproducible measurements of TSP-1, PF-4 and VEGF. Blood collection by venflon or inadvertent hemolysis during blood withdrawal caused significantly elevated TSP-1 and PF4 values. When optimized plasma preparation was applied, a significant increase of TSP-1 and VEGF in cancer patients was detected (P = 0.006; P < 0.001). Conclusion: The reliable plasma analysis of circulating platelet-stored angiogenesis factors requires preparation with CTAD at 4°C and blood collection by butterfly needle. Suboptimal procedures of plasma preparation are commonly applied in clinical monitoring of angiogenesis parameters which may account for the differences in reported plasma values and may have masked their predictive or prognostic marker potential. IOS Press 2011 2011-09-06 /pmc/articles/PMC3826483/ /pubmed/21896999 http://dx.doi.org/10.3233/DMA-2011-0798 Text en Copyright © 2011 Hindawi Publishing Corporation.
spellingShingle Other
Starlinger, Patrick
Alidzanovic, Lejla
Schauer, Dominic
Brugger, Philipp
Sommerfeldt, Silvia
Kuehrer, Irene
Schoppmann, Sebastian F.
Gnant, Michael
Brostjan, Christine
Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts
title Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts
title_full Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts
title_fullStr Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts
title_full_unstemmed Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts
title_short Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts
title_sort platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts
topic Other
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826483/
https://www.ncbi.nlm.nih.gov/pubmed/21896999
http://dx.doi.org/10.3233/DMA-2011-0798
work_keys_str_mv AT starlingerpatrick plateletstoredangiogenesisfactorsclinicalmonitoringispronetoartifacts
AT alidzanoviclejla plateletstoredangiogenesisfactorsclinicalmonitoringispronetoartifacts
AT schauerdominic plateletstoredangiogenesisfactorsclinicalmonitoringispronetoartifacts
AT bruggerphilipp plateletstoredangiogenesisfactorsclinicalmonitoringispronetoartifacts
AT sommerfeldtsilvia plateletstoredangiogenesisfactorsclinicalmonitoringispronetoartifacts
AT kuehrerirene plateletstoredangiogenesisfactorsclinicalmonitoringispronetoartifacts
AT schoppmannsebastianf plateletstoredangiogenesisfactorsclinicalmonitoringispronetoartifacts
AT gnantmichael plateletstoredangiogenesisfactorsclinicalmonitoringispronetoartifacts
AT brostjanchristine plateletstoredangiogenesisfactorsclinicalmonitoringispronetoartifacts